Six top tips to prepare for the new EU Clinical Trial Regulation

The European Union Clinical Trial Regulation 536/2014 (EU-CTR) aims to standardize and harmonize the conduct and management of interventional clinical trials across the European Economic Area (EEA), with legally binding rules on requirements and increased transparency. The new EU-CTR promises a simplified process designed to decrease the burden resulting from idiosyncratic interpretations of the current EU-CTD. But to reap efficiencies, sponsors must sow operational changes. This article covers the six essential preparations companies should undertake now.


Open PDF

Return to Insights Center

Related Insights

Article

Near-term strategies for biotech drug developers facing shifting healthcare dynamics

Feb 14, 2024

Blog

Ensuring future success in a new market by delivering a robust safety database solution

Aug 4, 2023

Article

Lessons from China and the United States on the use of RWE in regulatory submissions

Jul 19, 2021

Blog

Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market

Nov 13, 2023

Article

Expedited Pathways Comparisons - US EU CHN

Oct 19, 2021

Article

Australia: The Regulatory and Reimbursement Environment

Aug 28, 2023

Blog

Key implications for nonclinical development: FDA guidance on human gene therapy products incorporating human genome editing

Jul 1, 2024

Video

Cell & Gene Therapies: A Regulatory Update

Jul 22, 2022

Blog

Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions

May 16, 2022

Podcast

RBQM Podcast Series | Episode 3: Staying within the Guardrails: How to Push the Boundaries in a Highly Regulated Industry

Jun 16, 2022

Article

8 things you need to know about eCTDs in China

Jul 1, 2022

Blog

Preparing for the New Era of Hybrid Regulatory Inspections

Jul 11, 2022